Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

This pilot study is testing a personalized dendritic cell vaccine — a type of immune therapy made from your own immune cells and trained to recognize your specific tumor's mutations — in people with high-risk triple-negative breast cancer (TNBC) who still had significant cancer remaining after chemotherapy and surgery. **You may be eligible if...** - You are 18 or older - You have stage II or III triple-negative breast cancer (ER/PR ≤10%, HER2-negative) - You completed standard pre-surgery (neoadjuvant) chemotherapy and had surgery, but a significant amount of cancer remained (equivalent to residual cancer burden class II or III) - You have enough residual tumor tissue accessible to Moffitt Cancer Center for genetic sequencing to build the personalized vaccine - Your general health is good (ECOG 0–1) and your organ function meets study requirements **You may NOT be eligible if...** - You have metastatic (stage IV) breast cancer - You have a concurrent active cancer that could affect study safety - You have significant immune system problems or are taking medications that suppress your immune system - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.